β
Outcome MeasureQuality of Life

FSS

Fatigue Severity Scale

1 Paper in Blossom

Clinical Thresholds

963
No fatigue
Score 9–35
Significant fatigue
Score 36–63

Outcome Data Across Studies

Reported results for FSS across 1 study with quantitative data.

Outcome data across 1 study arm–timepoint observations
SD
Pilot study of psilocybin in patients with post-treatment lyme disease
2026Secondary
Psilocybin(experimental)020———

Papers Using FSS

Open Accessindividual

Pilot study of psilocybin in patients with post-treatment lyme disease

In an open‑label, single‑arm pilot study of 20 patients with post‑treatment Lyme disease, two psilocybin sessions with psychological support produced significant, sustained reductions in symptom burden (40% decrease in GSQ‑30 at six months) and improvements in both physical and mental quality of life. The intervention was feasible and well-tolerated with no serious related adverse events, supporting further controlled trials of psilocybin‑assisted therapy for PTLD.

Published
Journal
Scientific Reports
Authors
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., Aucott, J. N.

Quick Facts

Full Name
Fatigue Severity Scale
Domain
Quality of Life
Papers Indexed
1
Score Range
9–63
Interpretation
Lower = better
All Measures